Zomelis SR 100 Tablet contains Vildagliptin 100 mg, a potent oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance the incretin system by preventing the degradation of incretin hormones such as GLP-1 and GIP. This action results in increased insulin secretion and decreased glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Zomelis SR 100 is indicated as monotherapy or in combination with other antidiabetic agents, including metformin or insulin, for patients inadequately controlled by diet and exercise alone. The sustained-release formulation ensures a prolonged therapeutic effect, allowing once-daily dosing and improved patient compliance. It is essential to monitor renal function periodically during treatment, as dose adjustments may be necessary in patients with renal impairment. Common adverse effects include headache, dizziness, and mild gastrointestinal disturbances, while serious adverse events are rare. Zomelis SR 100 should be used under medical supervision, with regular monitoring of blood glucose levels to optimize therapy and minimize risks. It is not indicated for type 1 diabetes or diabetic ketoacidosis.